Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: A review of the evidence

Journal of Nephrology

Volumn 22, Issue 5, 2009, Pages 598-609

  Kanbay, Mehmet ^a,d   Turgut, Faruk ^a   Covic, Adrian ^b   Goldsmith, David ^c  

^a FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

^b C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^c GUY S HOSPITAL   (United Kingdom)

^d Gokkusagi Mahallesi   (Turkey)

Author keywords

Chronic kidney disease; Dyslipidemia; End stage renal disease; Renal transplantation; Statin

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIALYSIS; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIPID METABOLISM; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; RENAL PROTECTION; REVIEW; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

EID: 70749147825     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Dirks JH, de Zeeuw D, Agarwal SK, et al; International Society of Nephrology Commission for the Global Advancement of Nephrology Study Group 2004. Prevention of chronic kidney and vascular disease: toward global health equity: the Bellagio 2004 Declaration. Kidney Int Suppl. 2005;98:S1-S6.
2. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis. 2001;38(Suppl 1):26-29.
3. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(Suppl 12):16-23.
4. Rattazzi M, Puato M, Faggin E, et al. New markers of accelerated atherosclerosis in end-stage renal disease. J Nephrol. 2003;16:11-20.
5. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol. 2003;14(Suppl 4):S315-S320.
6. McCullough PA, Soman S. Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor? Kidney Int Suppl. 2004;90:S18-S24.
7. Himmelfarb J. Oxidative stress in hemodialysis. Contrib Nephrol. 2008;161:132-137.
8. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial. 2002;15:329-337.
9. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24:469-473.
10. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16:3403-3410.
11. Libby P. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
12. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(Suppl 3):S142-S156.
13. National Kidney Foundation. K/DOQI clinical practice guidelines on managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41:S1-S77.
14. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
15. Wanner C, Krane V, März W, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
16. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140:167-174.
17. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl. 1991;31:S29-S34.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
19. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728-734.
20. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290:F262-F272.
21. Liang K, Vaziri ND. Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure. Nephrol Dial Transplant. 1997;12:1381-1386.
22. Vaziri ND, Sato T, Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int. 2003;63:1756-1763.
23. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21:573-592.
24. Holvoet P, Donck J, Landeloos M, et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost. 1996;76:663-669.
25. Zhao Y, Marcel YL. Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry. 1996;35:7174-7180.
26. Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. 2006;10:1-7.
27. Vaziri ND, Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am J Physiol Renal Physiol. 2004;287:F1038-F1043.
28. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35:1-10.
29. Muhlestein JB, Anderson JL, Horne BD, et al; Intermountain Heart Collaborative Study Group. Early effects of statins in patients with coronary artery disease and high Creactive protein. Am J Cardiol. 2004;94:1107-1112.
30. Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005;165:725-730.
31. Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998;339:1972-1978.
32. Keech A, Simes RJ, Barter P, et al; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
33. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
34. Collins R, Armitage J, Parish S, et al; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
35. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557-1563.
36. Shepherd J, Kastelein JJ, Bittner V, et al; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448-1454.
37. Asselbergs FW, Diercks GF, Hillege HL, et al; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809-2816.
38. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45:473-484.
39. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297-304.
40. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation. 1996;61:1469-1474.
41. Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. 2001;60:1990-1997.
42. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation. 2001;27;72(2):223-7.
43. Sahu K, Sharma R, Gupta A, et al. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant. 2001;15:173-175.
44. Holdaas H, Fellström B, Jardine AG, et al; Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024-2031.
45. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16:3748-3754.
46. Shepherd J, Kastelein JP, Bittner VA, et al; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008;83:870-879.
47. Keane WF, Kasiske BL, O'Donnell MP, et al. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis. 1991;17(Suppl 1):38-42.
48. Vázquez-Parez S, Aragoncillo P, de Las Heras N, et al. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrol Dial Transplant. 2001;16(Suppl 1):40-44.
49. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-269.
50. Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006-2016.
51. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: metaanalysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645-651.
52. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565-570.
53. Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol. 2005;96:1290-1292.
54. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145:117-124.
55. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006-2016.
56. Kanbay M, Yildirir A, Bozbas H, et al. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail. 2005;27:297-303.
57. Borghi C, Dormi A, Veronesi M, et al; Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J. 2004;148:285-292.
58. Isbel NM, Haluska B, Johnson DW, et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J. 2006;151:745-753.
59. Fellström B, Holdaas H, Jardine AG, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res. 2007;30:314-322.
60. Landray M, Baigent C, Leaper C, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006;47:385-395.
61. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;84:S207-S210.
62. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996;7:158-165.
63. Kanbay M, Yildirir A, Akcay A, et al. Effects of immunosuppressive drugs on serum lipid levels in renal transplant recipients. Transplant Proc. 2006;38:502-505.
64. Fellström B, Holdaas H, Jardine A. Cardiovascular disease in renal transplantation: Management by statins. Transplant Rev. 2004;18:122-128.
65. Cosio FG, Pesavento TE, Kim S, et al. Patient survival after renal transplantation: Part IV: impact of post-transplant diabetes. Kidney Int. 2002;62:1440-1446.
66. Zhang W, Liu M, Wu Y, et al. Protective effects of atorvastatin on chronic allograft nephropathy in rats. J Surg Res. 2007;143:428-436.
67. Del Castillo D, Cruzado JM, Manel Díaz J, et al. The effects of hyperlipidaemia on graft and patient outcome in renal transplantation. Nephrol Dial Transplant. 2004;19(Suppl 3):iii67-iii71.
68. Masterson R, Hewitson T, Leikis M, et al. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation. 2005;80:332-338.
69. Türk TR, Voropaeva E, Kohnle M, et al. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant. 2008;23:369-373.
70. Lisik W, Schoenberg L, Lasky RE, et al. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen. Transplant Proc. 2007;39:3086-3092.
71. Fellström B, Holdaas H, Jardine AG, et al; Assessment of Lescol in Renal Transplantation Study Investigators. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int. 2004;66:1549-1555. 72. Lentine KL, Brennan DC. Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrol Dial Transplant. 2004;19:2378-2386.
72. Holdaas H, Fellström B, Cole E, et al; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929-2936.
73. Jardine AG, Holdaas H. Fluvastatin in combination with cyclosporine in renal transplant recipients: a review of clinical and safety experience. J Clin Pharm Ther. 1999;24:397-408.